Vericel Corporation notice of data transfer Skip to content

Notice of Data Transfer

On June 2, 2014, Vericel Corporation ("Vericel"), formerly known as Aastrom Biosciences, announced that it had completed its acquisition of Sanofi's cell therapy and regenerative medicine business unit. In the course of its ordinary business activities and in compliance with the applicable laws and regulations, Sanofi and/or its authorized affiliates collected information on Healthcare Professionals (HCP's) patients, and other individuals throughout the world. Such data will be transferred to or accessed by Vericel employees or affiliates within the United States, internally within Vericel or by external third parties, who may process personal data as directed by Vericel, or disclosed by Vericel for use on its behalf to comply with the applicable laws and regulations relating to donation, procurement, testing, processing, storage and distribution of tissues and cells. The collection, compilation, analysis and delivery of personal data are governed nationally and regionally by personal data protection laws and regulations.

Indication and Important Safety Information

Important Safety Information

MACI should not be used if you:

  • are allergic to antibiotics such as gentamicin, or materials that come from cow, pig, or ox;
  • have severe osteoarthritis of the knee, other severe inflammatory conditions, infections or inflammation in the bone joint and other surrounding tissue, or blood clotting conditions;
  • have had knee surgery in the past 6 months, not including surgery for obtaining a cartilage biopsy or a surgical procedure to prepare your knee for a MACI implant;
  • or cannot follow a doctor-prescribed rehabilitation program after your surgery

Consult your doctor if you have cancer in the area of the cartilage biopsy or implant as the safety of MACI is not known in those cases.

Conditions that existed before your surgery, including meniscus tears, joint or ligament instability, or alignment problems should be evaluated and treated before or at the same time as the MACI implant.

MACI is not recommended if you are pregnant.

MACI has not been studied in patients younger than 18 or over 55 years of age.

Common side effects include joint pain, tendonitis, back pain, joint swelling, and joint effusion.

More serious side effects include joint pain, cartilage or meniscus injury, treatment failure, and osteoarthritis.

Please see Full Prescribing Information for more information.

Indication

MACI® is made up of your own (autologous) cells that are expanded and placed onto a film that is implanted into the area of the cartilage damage and absorbed back into your own tissue.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is made up of your own (autologous) cells that are expanded and placed onto a film that is implanted into the area of the cartilage damage and absorbed back into your own tissue.

MACI is used for the repair of symptomatic cartilage damage of the adult knee.

The amount of MACI applied depends on the size of the cartilage damage. The MACI film is trimmed by your surgeon to match the size and shape of the damage, to ensure the damaged area is completely covered.

Limitations of Use

It is not known whether MACI is effective in joints other than the knee.

It is not known whether MACI is safe or effective in patients over the age of 55 years.